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Abstract: The purpose of this study was to examine the association between the different types of
treatment for diabetes and depressive symptoms. In particular, this study assessed the presence of
depressive symptoms in patients with diabetes who are undergoing pharmacological treatments
in terms of sex. This study used data from the 2011–2016 Korea Community Health Survey, which
included responses from 50,774 male and 48,978 female participants with diabetes who were receiving
pharmacological treatments. Patients aged ≥30 years were included. Logistic regression analysis
was conducted to examine the significance of the association. Male participants treated with insulin
injection were more likely to experience depressive symptoms than those taking oral hypoglycemic
(oral agents) only (odds ratio (OR) = 1.27; 95% confidence interval (CI): 1.04–1.56). Male patients
treated with both oral agents and insulin injection had the highest OR value of depressive symptoms
among different types of treatments (OR = 1.41, 95% CI: 1.25–1.60). The same tendency was observed
in female participants. In female patients, however, the association between depressive symptoms
and insulin injection was statistically insignificant (both oral agents and insulin injection OR = 1.35,
95% CI: 1.22–1.50, insulin injection OR = 1.17, 95% CI: 0.98–1.41). The association between depressive
symptoms and the type of diabetes treatment was more significant in male than in female patients.
Those who were treated with oral agents and insulin injection were more likely to have depressive
symptoms than those receiving oral agents of treatment.
Keywords: diabetes mellitus; depression; therapeutics; drug therapy; insulin
1. Introduction
Diabetes is a non-communicable disease [1]. However, its prevalence is increasing worldwide [2].
According to International Diabetes Federation (IDF) data, the number of individuals with diabetes
worldwide in 2017 was approximately 424.9 million, with a prevalence rate of 8.8%. Moreover, in
2045, its prevalence is predicted to increase up to 9.9% among 6.37 billion adults worldwide [3].
The increase in its prevalence is a cause of concern because diabetes is one of the major causes of death.
According to the World Health Organization (WHO) data, diabetes is the sixth leading cause of death
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in 2015, with 1.59 million recorded cases [4]. The leading cause of death among diabetes patients is
diabetes complications.
Blood glucose levels that are poorly managed increase the risk of these complications [5]. In other
words, uncontrolled diabetes can cause complications, which can threaten the lives of patients.
Therefore, the blood glucose levels (pharmacological or non-pharmacological treatment) of patients
with diabetes must be controlled. If the blood glucose levels of patients with diabetes is properly
controlled, diabetes-related complications and death can be prevented [3].
In contrast, depression increases the risk of complications and death among individuals with
diabetes. Depression is a well-known comorbidity in patients with chronic diseases, and diabetes is not
an exception [6]. Distress from the condition, depressive mood or symptoms, and clinical depression
can be observed in patients with diabetes [7]. Depressive symptoms in patients with diabetes reduces
adherence to treatments [8] and disrupts the management of high blood glucose. Moreover, they can
cause complications and increase the risk of mortality from diabetes [3,9]. Diabetes patients with
depression have approximately 1.5 times increased risk of mortality compared to diabetes patients
without depression [10]. Thus, depression is fatal in these patients.
In several previous studies, diabetes and depressive symptoms had a bidirectional association [11].
Both are risk factors that cause each other to occur, and they also exacerbate each other’s disease
state. Therefore, individuals with diabetes have twice the increased risk for depression than those
without [12,13]. In particular, among patients with diabetes, emotional distress (including depressive
symptoms) is more commonly observed in women than in men [14,15]. Approximately 80% of patients
with diabetes are more likely to experience a recurrence of depressive symptoms [16]. Furthermore,
treatments for high blood glucose had a negative impact on depression [17–20].
According to previous studies, the degree of depressive symptoms among patients with diabetes
differed according to the type of treatment for diabetes. Studies that used the problem areas in diabetes
(PAID) questionnaire focused on depression, and the emotional problems of the patients with diabetes
showed different emotional distresses, which depends on the type of treatment for type 2 diabetes [15].
In another study that used the PAID questionnaire, the scores of the IDDM (insulin dependent diabetes
mellitus) and NIDDM (non-insulin-dependent diabetes mellitus) groups differed in terms of the type
of diabetes treatment [21]. In addition, in a study by Black on older Mexican Americans with diabetes,
the current type of diabetes treatment was associated with depressive symptoms [22]. The study by
Hermanns showed the difference in the proportion of individuals with type 1 and 2 diabetes without
insulin treatment and those with type 2 diabetes with insulin treatment who were diagnosed with
clinical and subclinical depression [23].
Therefore, the present study aimed to examine the association between the different types of
diabetes treatment and depressive symptoms. In particular, the depressive symptoms of patients with
diabetes who were on pharmacologic treatments (oral agents, insulin injection, and both oral agent
medications and insulin injection) were assessed in terms of sex.
2. Materials and Methods
2.1. Data Collection and Participants
This study used data from The Korea Community Health Survey (CHS) in 2011–2016. The CHS is
a cross-sectional, annual, nationwide public health survey, which has been performed by the Korea
Center for Disease Control and Prevention (KCDC) since 2008. The surveyed population is registered
adult residents aged 19 years and older in the community health center. The sample design is a
complex, stratified, multistage, probability-cluster sampling design. The survey is conducted by a
trained interviewer in a one-on-one interview in Korean through computer-assisted personal interview
(CAPI) [24]. The CHS data are openly published. Additionally, participants’ information was fully
anonymized and unidentified prior to analysis. Accordingly, ethical approval was not required for this
study. Ethical approval of the CHS was obtained from the KCDC (2010-02CON-22-P; 2011-05CON-04-C;
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2012-07CON-01-2C; 2013-06EXP-01-3C; 2014-08EXP-09-4C-A; 2016-10-01-P-A). The dataset is available
on The CHS website (https://chs.cdc.go.kr/chs/index.do).
The total number of respondents in this survey was 1,372,650. However, only respondents aged
30 years or older (n = 1,220,729) were selected. Two-stage filtering was performed to identify patients
with diabetes who were undergoing treatment. First, patients who answered yes to the question “Have
you ever been diagnosed with diabetes by a doctor?” were included (n = 128,474). Second, only those
who answered yes to the question “Are you currently being treated?” were included among them
(n = 115,990). There were no missing data in the questionnaire that asked for the types of diabetes
treatment. Individuals with missing data on covariate variables were further excluded. Therefore, a
final sample population of 99,752 was included in the analysis. Of these, 50,774 were male and 48,978
were female.
2.2. Dependent Variable
Self-reported depressive symptom was considered as a dependent variable. The following
question was included in the questionnaire: “Have you ever felt sad or desperate enough to cause
disruption to your daily life over two consecutive weeks in the last year?” The respondents were
classified who answered yes as having depressive symptoms and those who answered no as having no
depressive symptoms. Those who responded with “Don’t know” and “No response” were excluded.
2.3. Independent Variable
The type of diabetes treatment used to control blood glucose was considered an independent
variable. This study used the CHS question “What is the treatment you are doing to manage your
blood glucose? Please answer all” to set the interest variable. The possible responses to the questions
include the following: insulin injections (yes, no), oral agent medications (oral agents; yes, no),
non-pharmacologic therapy (exercise, diet; yes, no). Among the patients, those who answered that
they were only treated with non-pharmacological therapy were excluded to examine the association
between the different type of pharmacological diabetes treatments and depression.
2.4. Control Variables
The covariates were as follows: age, socioeconomic (SES) factors, health-related factors, and the
year of the survey. For SES factors, educational level, marital status, occupation (white collar, pink
collar, blue collar, and others), monthly household income, and region of residence were considered.
The monthly household income was categorized into six groups. At the start of the investigation,
1000 KRW was equivalent to 0.93 USD [25]. Health-related factors included alcohol status (whether
they drink more than one cup of alcohol during their lifetime), smoking status (whether they smoke
more than five packs during their lifetime), walking activities, perceived health status, perceived stress,
body mass index, and a history or diagnosis of hypertension and dyslipidemia. Walking activities were
assessed by using the following questionnaire: “How many days did you walk at least 10 minutes at a
time in the last week?” The responses were classified as follows: None or 1 day per week as inactive,
2–3 days a week as low, 4–5 days a week as middle, and 6–7 days a week as high.
2.5. Statistical Analysis
χ2 test and logistics regression analysis were used for the analysis. All the analyses were
performed by classifying the patients according to sex (male and female). χ2 test was used to examine
the significant difference in depressive symptoms depending on the different types of pharmacological
treatments for diabetes and to control covariates, such as age, SES factors, health-related factors,
and year. A p value <0.05 was considered statistically significant. Logistic regression analysis was
conducted to determine adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup
analysis was performed according to the different types of treatments for diabetes and depressive
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symptoms. Statistical analyses were performed by using the Statistical Analysis System software
version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Study Population
Table 1 shows the general characteristics of the study population. Of the total diabetes patients
who were undergoing diabetes treatment, 90,182 (90.4%) were treated with oral agents and 7049 (7.1%)
were treated with oral agents and insulin injection. Insulin injection was the least used (2521; 2.5%).
Among the male and female diabetes patients, 2911 (2.9%) and 5207 people (5.2%) had depressive
symptoms, respectively, indicating a higher proportion of women affected. As for the depressive
symptoms according to the type of treatment, in men, treatment with both oral agents and insulin
injection were the most frequently used at 5.7%, followed by insulin injection at 5.1%. Oral agents
were the least frequently used at 2.6%. In women, treatment with both oral agents and insulin injection
were the most frequently used at 8.2%, followed by insulin injection at 6.2%. Oral agents were the least
frequently used at 5.0%.
Table 1. General characteristics of the study population with depressive symptoms.
Variables Total
Male
p-Value *
Female
p-Value *Yes No Yes No
N % N % N % N % N %
Total 99,752 100.0 2911 2.9 47,863 48.0 5207 5.2 43,771 43.9
Diabetes treatment <0.0001 <0.0001
Oral agents 90,182 90.4 2384 2.6 43,415 48.1 4471 5.0 39,912 44.3
Insulin injection 2521 2.5 128 5.1 1273 50.5 157 6.2 963 38.2
Oral agents and insulin
injection 7049 7.1 399 5.7 3175 45.0 579 8.2 2896 41.1
Age <0.0001 0.0006
30–39 1396 1.4 79 5.7 780 55.9 67 4.8 470 33.7
40–49 7528 7.5 286 3.8 4402 58.5 343 4.6 2497 33.2
50–59 21,613 21.7 738 3.4 11,794 54.6 1011 4.7 8070 37.3
60–69 32,185 32.3 850 2.6 15,683 48.7 1592 4.9 14,060 43.7
70–79 29,785 29.9 793 2.7 12,594 42.3 1774 6.0 14,624 49.1
80~ 7245 7.3 165 2.3 2610 36.0 420 5.8 4050 55.9
Educational level <0.0001 0.2868
Elementary school or less 44,717 44.8 879 2.0 12,627 28.2 3337 7.5 27,874 62.3
Middle school 18,166 18.2 607 3.3 9650 53.1 822 4.5 7087 39.0
High school 24,168 24.2 925 3.8 15,642 64.7 831 3.4 6770 28.0
College or over 12,701 12.7 500 3.9 9944 78.3 217 1.7 2040 16.1
Marital status <0.0001 <0.0001
Married-cohabit 72,774 73.0 2022 2.8 41,690 57.3 2768 3.8 26,294 36.1
Married non-cohabitant or
bereaved or divorced 25,153 25.2 716 2.8 4972 19.8 2371 9.4 17,094 68.0
Unmarried 1825 1.8 173 9.5 1201 65.8 68 3.7 383 21.0
Occupation <0.0001 <0.0001
White collar 7244 7.3 246 3.4 5855 80.8 90 1.2 1053 14.5
Pink collar 8424 8.4 164 1.9 3838 45.6 392 4.7 4030 47.8
Blue collar 32,561 32.6 752 2.3 20,694 63.6 826 2.5 10,289 31.6
Others 51,523 51.7 1749 3.4 17,476 33.9 3899 7.6 28,399 55.1
Monthly household
income, 1000 KRW <0.0001 <0.0001
~999 35,161 35.2 1370 3.9 12,982 36.9 2683 7.6 18,126 51.6
1000–1999 22,848 22.9 603 2.6 11,569 50.6 1092 4.8 9584 41.9
2000–2999 15,729 15.8 377 2.4 8401 53.4 627 4.0 6324 40.2
3000–3999 10,287 10.3 242 2.4 5714 55.5 321 3.1 4010 39.0
4000–4999 6181 6.2 120 1.9 3535 57.2 212 3.4 2314 37.4
5000~ 9546 9.6 199 2.1 5662 59.3 272 2.8 3413 35.8
Residency region <0.0001 <0.0001
Urban area–large city 23,897 24.0 833 3.5 11,457 47.9 1458 6.1 10,149 42.5
Urban area–small city 18,580 18.6 592 3.2 8790 47.3 1041 5.6 8157 43.9
Rural area 57,275 57.4 1486 2.6 27,616 48.2 2708 4.7 25,465 44.5
Alcohol status 0.5162 <0.0001
Ever 73,066 73.2 2640 3.6 43,232 59.2 3074 4.2 24,120 33.0
Never 26,686 26.8 271 1.0 4631 17.4 2133 8.0 19,651 73.6
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Table 1. Cont.
Variables Total
Male
p-Value *
Female
p-Value *Yes No Yes No
N % N % N % N % N %
Smoking status 0.0476 <0.0001
Ever 44,517 44.6 2413 5.4 38,972 87.5 623 1.4 2509 5.6
Never 55,235 55.4 498 0.9 8891 16.1 4584 8.3 41,262 74.7
Walking activity <0.0001 <0.0001
Inactive 29,997 30.1 1062 3.5 14,062 46.9 1851 6.2 13,022 43.4
Low 15,902 15.9 438 2.8 7364 46.3 873 5.5 7227 45.4
Middle 13,996 14.0 372 2.7 6453 46.1 711 5.1 6460 46.2
High 39,857 40.0 1039 2.6 19,984 50.1 1772 4.4 17,062 42.8
Perceived health status <0.0001 <0.0001
Good 13,026 13.1 160 1.2 8543 65.6 190 1.5 4133 31.7
Normal 34,556 34.6 628 1.8 19,126 55.3 890 2.6 13,912 40.3
Bad 52,170 52.3 2123 4.1 20,194 38.7 4127 7.9 25,726 49.3
Perceived stress level <0.0001 <0.0001
Very 25,887 26.0 1863 7.2 10,076 38.9 3443 13.3 10,505 40.6
Less 45,860 46.0 832 1.8 22,838 49.8 1412 3.1 20,778 45.3
Low 28,005 28.1 216 0.8 14,949 53.4 352 1.3 12,488 44.6
Body mass index (kg/m2) <0.0001 <0.0001
Underweight (~18.4) 2959 3.0 163 5.5 996 33.7 295 10.0 1505 50.9
Normal weight (18.5–22.9) 33,982 34.1 1040 3.1 15,412 45.4 1794 5.3 15,736 46.3
Overweight (23.0–24.9) 27,470 27.5 754 2.7 14,260 51.9 1198 4.4 11,258 41.0
Obesity (25.0~) 35,341 35.4 954 2.7 17,195 48.7 1920 5.4 15,272 43.2
Hypertension diagnosis 0.0027 0.0732
Yes 60,434 60.6 1752 2.9 27,451 45.4 3379 5.6 27,852 46.1
No 39,318 39.4 1159 2.9 20,412 51.9 1828 4.6 15,919 40.5
Dyslipidemia diagnosis <0.0001 <0.0001
Yes 32,578 32.7 1078 3.3 13,732 42.2 2308 7.1 15,460 47.5
No 67,174 67.3 1833 2.7 34,131 50.8 2899 4.3 28,311 42.1
Year <0.0001 <0.0001
2011 14,080 14.1 362 2.6 6660 47.3 627 4.5 6431 45.7
2012 14,856 14.9 351 2.4 7209 48.5 663 4.5 6633 44.6
2013 16,061 16.1 462 2.9 7753 48.3 812 5.1 7034 43.8
2014 17,230 17.3 591 3.4 8204 47.6 1042 6.0 7393 42.9
2015 18,280 18.3 582 3.2 8746 47.8 993 5.4 7959 43.5
2016 19,245 19.3 563 2.9 9291 48.3 1070 5.6 8321 43.2
* p-value is the result of the chi square test. Oral agents, Oral hypoglycemics; KRW, Korean Won;
3.2. Association between Type of Diabetes Treatment and Depressive Symptoms
Table 2 shows the results of the factors associated with the depressive symptoms of the diabetes
patients. The logistic regression analyses adjusted for covariates revealed that the type of diabetes
treatment was related to the depressive symptoms of the diabetes patients. In addition, the type of
diabetes treatment was more closely related to the symptoms of depression in men with diabetes than
in women with diabetes. Compared with taking oral agents, in both men and women, insulin injections
more likely caused depressive symptoms. However, the results of women were not significant as
compared with those of men (OR = 1.27; 95% CI: 1.04–1.56 vs OR = 1.17, 95% CI: 0.98–1.41). The male
and female diabetes patients who received oral agents and insulin injections were the most likely
to have depressive symptoms than the diabetes patients with one type of treatment. This showed
statistically significant results for both men and women (OR = 1.41, 95% CI: 1.25–1.60 and OR = 1.35,
95% CI: 1.22–1.50, respectively).
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Table 2. Factors associated with depressive symptoms in diabetes patients.
Variables
Male Female
Adjusted OR 95% CI Adjusted OR 95% CI
Diabetes treatment
Oral agents 1.00 - 1.00 -
Insulin injection 1.27 (1.04–1.56) 1.17 (0.98–1.41)
Oral agents and insulin injection 1.41 (1.25–1.60) 1.35 (1.22–1.50)
Age
30–39 1.00 - 1.00 -
40–49 0.71 (0.54–0.95) 1.20 (0.88–1.62)
50–59 0.73 (0.56–0.97) 1.17 (0.87–1.56)
60–69 0.63 (0.48–0.84) 0.92 (0.68–1.24)
70–79 0.58 (0.44–0.78) 0.82 (0.61–1.11)
80~ 0.44 (0.32–0.62) 0.70 (0.51–0.96)
Educational level
Elementary school or less 1.00 - 1.00 -
Middle school 1.01 (0.90–1.14) 1.05 (0.96–1.15)
High school 0.96 (0.86–1.08) 1.12 (1.01–1.24)
College or over 0.90 (0.79–1.04) 1.10 (0.92–1.31)
Marital status
Married-cohabit 1.00 - 1.00 -
Married non-cohabitant or bereaved or divorced 1.93 (1.74–2.13) 1.40 (1.31–1.50)
Unmarried 1.41 (1.15–1.72) 1.26 (0.94–1.68)
Occupation
White collar 1.00 - 1.00 -
Pink collar 0.92 (0.74–1.13) 1.14 (0.88–1.48)
Blue collar 0.86 (0.72–1.02) 1.12 (0.87–1.45)
Others 1.81 (1.52–2.16) 1.78 (1.39–2.27)
Monthly household income, 1000 KRW
~999 1.00 - 1.00 -
1000–1999 0.69 (0.62–0.77) 0.82 (0.76–0.89)
2000–2999 0.63 (0.55–0.72) 0.73 (0.66–0.81)
3000–3999 0.58 (0.49–0.68) 0.58 (0.50–0.66)
4000–4999 0.48 (0.38–0.59) 0.71 (0.60–0.83)
5000~ 0.49 (0.40–0.58) 0.61 (0.53–0.71)
Residency region
Urban area–large city 1.00 - 1.00 -
Urban area–small city 0.84 (0.75–0.95) 0.84 (0.77–0.92)
Rural area 0.74 (0.67–0.81) 0.74 (0.69–0.80)
Alcohol status
Ever 1.00 - 1.00 -
Never 0.90 (0.78–1.03) 0.89 (0.83–0.95)
Smoking status
Ever 1.00 - 1.00 -
Never 1.10 (0.99–1.23) 0.67 (0.60–0.74)
Walking activity
Inactive 1.00 - 1.00 -
Low 0.94 (0.83–1.07) 0.94 (0.86–1.03)
Middle 0.95 (0.83–1.09) 0.95 (0.86–1.05)
High 0.86 (0.78–0.95) 0.90 (0.83–0.97)
Perceived health status
Good 1.00 - 1.00 -
Normal 1.44 (1.21–1.72) 1.14 (0.97–1.35)
Bad 2.53 (2.13–3.00) 1.90 (1.63–2.23)
Perceived stress level
Very 1.00 - 1.00 -
Less 0.24 (0.22–0.26) 0.24 (0.22–0.25)
Low 0.09 (0.08–0.11) 0.10 (0.09–0.11)
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Table 2. Cont.
Variables
Male Female
Adjusted OR 95% CI Adjusted OR 95% CI
Body mass index (kg/m2)
Underweight (~18.4) 1.51 (1.24–1.84) 1.45 (1.25–1.68)
Normal weight (18.5–22.9) 1.00 - 1.00 -
Overweight (23.0–24.9) 0.92 (0.83–1.02) 0.96 (0.88–1.04)
Obesity (25.0~) 0.92 (0.83–1.02) 0.98 (0.91–1.06)
Hypertension diagnosis
Yes 1.00 - 1.00 -
No 1.04 (0.96–1.14) 1.06 (0.99–1.13)
Dyslipidemia diagnosis
Yes 1.00 - 1.00 -
No 0.75 (0.69–0.82) 0.78 (0.73–0.84)
Year
2011 1.00 - 1.00 -
2012 0.89 (0.76–1.04) 1.06 (0.94–1.19)
2013 1.15 (0.99–1.34) 1.31 (1.16–1.47)
2014 1.36 (1.18–1.57) 1.58 (1.42–1.77)
2015 1.31 (1.13–1.51) 1.42 (1.27–1.59)
2016 1.17 (1.01–1.36) 1.52 (1.36–1.70)
Oral agents, Oral hypoglycemics; KRW, Korean Won.
3.3. Results of Subgroup Analyses
Table 3 shows the results of the subgroup analyses of the association of age, educational level,
walking activity, and body mass index with depressive symptoms. In most cases, in both men and
women, insulin injection showed higher OR values than the reference value for oral agents, but many
results of the subgroup analyses were not significant. In both men and women, oral agents and insulin
injection together had higher OR values than the reference value for oral agents, with most of the
patients showing significant results. The male patients treated with oral agents and insulin injection
showed that the age of 40 to 49 had the highest OR values (OR = 1.89, 95% CI: 1.28–2.81) and the age of
60–69 had the lowest OR values (OR = 1.28, 95% CI: 1.02–1.62). In body mass index, the OR value
of underweight was not significant and that of normal weight was the lowest (OR = 1.36, 95% CI:
1.11–1.67). The female treated with oral agents and insulin injection showed a similar trend to the
male except for body mass index. The age of 40–49 had the highest OR value (OR = 1.54, 95% CI:
1.04–2.28), and the results for the age of 60–69 were not significant. In body mass index, the OR value
of underweight was not significant. Normal weight had the highest OR value (OR = 1.46, 95% CI:
1.22–1.74), overweight had a lower OR value (OR = 1.35, 95% CI: 1.08–1.67), and obesity had the lowest
OR value (OR = 1.27, 95% CI: 1.07–1.50). This was a tendency different from the results of men.
Table 3. Subgroup analysis of depressive symptoms with the type of diabetes treatment by covariates *.
Variables
Diabetes Treatment
Oral Agents Insulin Injection Oral Agents and Insulin Injection
OR OR 95% CI OR 95% CI
Male
Age
30–39 + + +
40–49 1.00 0.98 (0.51–1.89) 1.89 (1.28–2.81)
50–59 1.00 1.17 (0.78–1.74) 1.53 (1.19–1.96)
60–69 1.00 1.47 (1.02–2.10) 1.28 (1.02–1.62)
70–79 1.00 1.26 (0.84–1.91) 1.34 (1.05–1.70)
80~ -
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Table 3. Cont.
Variables
Diabetes Treatment
Oral Agents Insulin Injection Oral Agents and Insulin Injection
OR OR 95% CI OR 95% CI
Educational level
Elementary school or less + + +
Middle school 1.00 1.38 (0.90–2.12) 1.36 (1.03–1.78)
High school 1.00 1.53 (1.10–2.12) 1.53 (1.23–1.91)
College or over 1.00 0.95 (0.55–1.65) 1.75 (1.30–2.35)
Walking activity
Inactive 1.00 1.31 (0.94–1.84) 1.55 (1.27–1.88)
Low 1.00 1.32 (0.76–2.32) 1.46 (1.03–2.06)
Middle 1.00 1.07 (0.60–1.89) 1.49 (1.04–2.13)
High 1.00 1.27 (0.91–1.78) 1.22 (0.98–1.52)
Body mass index (kg/m2)
Underweight (~18.4) 1.00 2.13 (1.00–4.54) 1.66 (0.98–2.79)
Normal weight (18.5–22.9) 1.00 1.33 (0.98–1.81) 1.36 (1.11–1.67)
Overweight (23.0–24.9) 1.00 1.33 (0.88–2.02) 1.46 (1.13–1.89)
Obesity (25.0~) 1.00 0.96 (0.62–1.50) 1.41 (1.13–1.76)
Female
Age
30–39 + + +
40–49 1.00 1.22 (0.67–2.22) 1.54 (1.04–2.28)
50–59 1.00 1.03 (0.67–1.57) 1.42 (1.12–1.80)
60–69 1.00 1.30 (0.93–1.83) 1.18 (0.98–1.42)
70–79 1.00 1.21 (0.86–1.71) 1.38 (1.15–1.64)
80~ -
Educational level
Elementary school or less + + +
Middle school 1.00 1.26 (0.80–1.98) 1.31 (1.01–1.70)
High school 1.00 1.09 (0.73–1.63) 1.45 (1.12–1.88)
College or over 1.00 0.76 (0.36–1.60) 1.84 (1.15–2.95)
Walking activity
Inactive 1.00 1.32 (0.98–1.78) 1.45 (1.23–1.72)
Low 1.00 1.08 (0.66–1.76) 1.39 (1.08–1.79)
Middle 1.00 1.80 (1.11–2.89) 1.23 (0.91–1.66)
High 1.00 0.88 (0.62–1.24) 1.24 (1.04–1.49)
Body mass index (kg/m2)
Underweight (~18.4) 1.00 1.14 (0.56–2.35) 1.27 (0.79–2.03)
Normal weight (18.5–22.9) 1.00 1.03 (0.76–1.40) 1.46 (1.22–1.74)
Overweight (23.0–24.9) 1.00 1.28 (0.87–1.88) 1.35 (1.08–1.67)
Obesity (25.0~) 1.00 1.30 (0.94–1.79) 1.27 (1.07–1.50)
+: The number is insufficient and cannot be calculated; * Age, sex, educational level, marital status, occupation,
monthly household income, residency region, alcohol status, smoking status, perceived health status, walking
activity, stress level, body mass index, hypertension diagnosis, dyslipidemia diagnosis, and year variables were
adjusted. Oral agents, Oral hypoglycemics;
4. Discussion
This study investigated the association between the types of treatment and depressive symptoms
among diabetes patients undergoing diabetes treatment by dividing sex, using nationally represented
data. The depressive symptoms in both male and female patients treated with diabetes varied
according to the type of diabetes treatment. In all diabetes patients undergoing diabetes treatment,
women reported more depressive symptoms than men. However, in examining the factors of
depressive symptoms, it was found that men were more affected by depressive symptoms than
women, depending on the type of diabetes treatment. As with the previous investigation, the overall
likelihood of experiencing depressive symptoms in all the diabetes patients was higher for women
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than for men [12,26]. However, according to type of treatment, men had a greater risk of experiencing
depressive symptoms than women [27].
In the male diabetes patients, in line with previous studies [15,22,23], showed that treatment
with “oral agent and insulin injection” or “insulin injection” was more likely to cause depressive
symptoms than treatment with “oral agent” alone. Consistently with a previous study, the patients
who were using insulin showed more depressive symptoms. In the Sample description section of
the study by Hermanns, of 376 diabetes patients, 53 had clinical depression. Of these patients, 16
were receiving type 1 diabetes treatment (30.2%); 11 were receiving type 2 diabetes treatment without
insulin treatment (20.8%); and 26 were receiving type 2 diabetes treatment with insulin (49.0%). Of
the 71 patients with subclinical depression, 31%, 22.5% and 46.5% were receiving the aforementioned
treatments, respectively [23].
In female diabetes patients, oral agents and insulin injection significantly caused more depressive
symptoms than oral agents alone according to statistics. Statistically significant results for insulin
injection were difficult to obtain. However, the characteristics of the study population in our study
showed that treatment with insulin injection resulted in a higher proportion of patients with depressive
symptoms than treatment with oral agents. Previous studies showed that treatment with insulin
injection affects depressive symptoms in diabetes patients. In a study that used PAID questionnaires
to investigate the treatment methods for type 2 diabetes patients and their relationship to emotional
distresses, the mean PAID score was 14.7 in the “diet alone” group and 17.8 in the “oral medication”
group. “Insulin” had the highest score of 24.6 [15]. In Black’s study of older Mexican American
diabetes patients, “insulin” had the highest OR value (OR = 1.83; 95% CI: 1.30–2.59), followed by “both
insulin and OHA (oral hypoglycemic agent)” (OR = 1.79; 95% CI: 1.10–2.89). “OHAs” had the lowest
OR value (OR = 0.72; 95% CI: 0.51–0.99) [22].
Our results for the male patients showed that the OR was highest for the oral agents and insulin
injection group. That is, patients who took both oral agent medication and insulin injection tended to
show depressive symptoms more often than patients who were treated only with insulin. In Welch’s
study that used PAID, the mean PAID score was lowest for “diet treated” at 10.5 ± 12.8 and highest for
“IDDM” at 32.9 ± 20.2. For the “NIDDM” groups, including “insulin treated” (26.4 ± 20.8) and “tablet
treated” (24.9 ± 22.1), the score was 25.0 ± 20.9 [21]. Hermanns reported that PAID questionnaires
are useful to examine the depression and emotional problems of diabetes patients [23]. Therefore,
depressive symptoms in patients taking oral medications should not be overlooked. In conclusion, in
this study, the diabetes patients who were undergoing diabetes treatment only showed differences in
the degree of depressive symptoms depending on their sex and type of diabetes treatment, and all
were vulnerable to the risk of depressive symptoms.
This study performed subgroup analyses of depressive symptoms and type of diabetes treatments
according to age and body mass index. The results showed that the diabetes patient had a stronger
association with depressive symptoms if they used both oral agents and insulin injection. Both male
and female patients who received oral agents and insulin injection treatment were most likely to
experience depressive symptoms at the age of 40–49 years. This is consistent with previous studies
that showed that depression was more prevalent among diabetes patients aged 40–49 years [28].
Body mass index showed a different trend in the male and female patients. The normal-weight men
had the lowest prevalence of depressive symptoms, while the women had the highest prevalence of
depressive symptoms. Women were at higher and lower risks of experiencing depression when they
were normal-weight and obese, respectively. This is considered to have been affected by the mental
stress of the female to achieve normal weight due to the climate of Korean society, in which women
care more about their weight than men.
Diabetes patients with depression have a lower quality of life and are less active in disease
management than diabetes patients without depression [8,29]. Low quality of life and poor management
of diseases worsens the depressive symptoms of diabetes patients with depression and eventually
leads to a vicious circle that continues to degrade their health and quality of life. Therefore, managing
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depression in diabetics is very important. Our research is meaningful because we have again
emphasized depression in diabetes patients by observing the association between the type of diabetes
treatment and depressive symptoms among patients with diabetes. In addition, the bidirectional
relationship between diabetes and depressive symptoms is well known [11]. However, regardless of
whether depression adversely affects diabetes or diabetes adversely affects depression, all diabetes
patients need treatments to manage their blood glucose. Therefore, our study is significant in that
it demonstrates the association between the type of diabetes treatment and depressive symptoms.
Furthermore, the strength of our study is that the depressive symptoms of diabetes patients were
studied according to sex. Our research has the strength of its results being generalizable to the Korean
adult population, as it used nationally representative data.
However, this study has some limitations, as it is conducted only with the aforementioned data.
First, due to the bidirectional relationship between diabetes and depression [11], depression may occur
before diabetes onset or treatment. On the contrary, diabetes can lead to or exacerbate depression,
which can be caused by the burden of the disease (time, cost, effort) as well as by pathophysiological
mechanisms [15,30]. Furthermore, if a patient with diabetes neglects to manage diabetes due to
depression, the symptoms of diabetes may worsen. However, because the data is cross-sectional
in design, the causal relationship between diabetes treatment and depressive symptoms remains
unknown. In addition, due to the limitation of the survey items, it was not possible to know when
diabetes and depression onset or when they were diagnosed and to know time, cost and efforts
to manage diabetes. Therefore, it was not possible to detect patients who already had depression
and to estimate the burden of disease in diabetes patients. Second, the presented data such as the
depressive symptoms and health status variables were self-reported. Therefore, recall bias was possible.
In addition, we used one question that asked about depressive symptoms rather than an objective
depression inventory. Moreover, that question was about perceived depressive symptoms. Because
there were no questions asked about the depression diagnosis or depression inventory, the responses
to the feelings of sadness or depression for >2 weeks in a year were considered depressive symptoms.
Third, the questions about diabetes were inadequate. None of the questions were about the type,
duration, severity of diabetes, and glycemic control. Information about diabetes is important because
it is closely related to the depressive symptoms and the strategy of treatment may vary accordingly.
According to the Treatment Guideline for Diabetes in Korea, insulin injections are prescribed for type
1 diabetes, while oral hypoglycemic agents are prescribed first for type 2 diabetes, and if glycemic
control is not good, use of both oral hypoglycemic agents and insulin injections is considered [31].
Therefore, type 2 diabetic patients who use both oral hypoglycemic agents and insulin injections may
have more severe symptoms of diabetes. However, it was impossible to pinpoint the type and severity
of diabetes in the data used in the study. In addition, diabetes duration is significantly associated
with depression [32]. However, it could not be adjusted because it was also unknown. Moreover, our
measures of the type of treatment for diabetes were based on single questions in the survey, which was
too wide to know the details. Thus, the more detailed forms of insulin treatment (injection, pump [33])
or the ingredients and type of oral agents (metformin, thiazolidinediones, dipeptidyl peptidase-4,
etc. [34]) could not be known. Also, how many times the patient took the oral agent or insulin injection
could not be known. Finally, treatment efficacy according to disease management and medication
adherence may be associated with depressive symptoms [35]. However, our study used cross-sectional
data, and the questionnaire did not include the efficacy of the medicine, the severity of the disease,
and the progress of the disease. Therefore, it is not possible to determine whether treatment efficacy
influences the results. These limitations require further study.
The bidirectional association of depressive symptoms with diabetes treatment effects and adherence
is also well recognized [11,20]. To prevent diabetes complications, blood glucose control should be
performed well, and to maintain blood glucose at a proper level, the risk of depression should be
avoided. Accordingly, physicians must also manage diabetes patients’ mental health, including
depressive symptoms. In addition, they should consider the depressive symptoms that diabetes
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patients may experience according to the type of diabetes treatment before the treatments are taken
into account.
5. Conclusions
This study shows the difference in depressive symptoms according to the type of treatment
among diabetes patients between the sexes. Depressive symptoms were more strongly associated
with diabetes treatment in male patients than in female patients. Insulin injection was associated
with depressive symptoms in diabetes patients. Oral agents and insulin injection had a significant
correlation with depressive symptoms in diabetes patients. Oral agents and insulin injection were
more likely to cause depressive symptoms than one form of treatment alone. Therefore, physicians
should consider diabetes patients’ risk for developing depressive symptoms according to sex and
the type of diabetes treatment. They should also include a process that provides mental support and
treatment when managing all diabetes patients.
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